NKGN VS CLGN Stock Comparison
Performance
NKGN10/100
10/100
NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
CLGN10/100
10/100
CLGN returned 0.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Volatility
NKGN10/100
10/100
NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
CLGN52/100
52/100
CLGN has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Technicals
NKGN
"Technicals" not found for NKGN
CLGN14/100
14/100
CLGN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.
Earnings
NKGN
"Earnings" not found for NKGN
CLGN10/100
10/100
CLGN has missed earnings 11 times in the last 20 quarters.
Profit
NKGN
"Profit" not found for NKGN
CLGN22/100
22/100
Out of the last 20 quarters, CLGN has had 4 profitable quarters and has increased their profits year over year on 3 of them.
All score calculations are broken down here to help you make more informed investing decisions
NKGen Biotech, Inc. Common Stock Summary
Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
CollPlant Biotechnologies Ltd Ordinary Shares Summary
Nasdaq / CLGN
Healthcare
Biotechnology
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NKGN to other companies in the same or a similar industry.